Navigation Links
92 Medicines and Vaccines now in Development for HIV/AIDS
Date:11/20/2007

WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Pharmaceutical researchers are testing 92 medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). December 1 marks the 20th anniversary of "World AIDS Day" -- a global awareness campaign that originated at the 1988 World Summit of Ministers of Health on Programmes for AIDS Prevention.

"We are greatly encouraged by the new, critically-important medicines and vaccines in development to treat and prevent HIV infection," says PhRMA President and CEO Billy Tauzin. "Pharmaceutical researchers are continuing their efforts to develop new therapies and vaccines to improve and lengthen the lives of HIV-infected patients."

The report found that of the 92 products in development, researchers are studying 20 vaccines and 46 antivirals. These drugs are either in human clinical trials or await approval by the U.S. Food and Drug Administration.

The report also lists 30 medicines to treat HIV/AIDS that have been approved since the virus that causes AIDS was first identified more than 20 years ago. The first such medicine was developed in 1987, just four years after the HIV virus was identified. The increased availability and utilization of newer prescription medicines has helped to reduce the U.S. death rate from AIDS substantially in recent years, according to government statistics.

Despite that progress, AIDS remains a devastating and growing worldwide health problem in developing countries, particularly in sub-Saharan Africa, China, India and the Russian Federation. According to the Joint United Nations Programme on HIV/AIDS, an estimated 32.7 million people worldwide lived with HIV at the end of 2006.

This year, that figure grew to an estimated 33.2 million people living with HIV, with an estimated 2.1 million people newly infected in 2007.

From 2000 to 2006, America's pharmaceutical research companies contributed more than $6.7 billion to improve health care in the developing world, according to the International Federation of Pharmaceutical Manufacturers & Associations. The projects they underwrote included building clinics to treat patients with HIV/AIDS, education and prevention programs, initiatives to prevent mother-to-child transmission of HIV, and donations of medicines for AIDS and related diseases. Companies also provide AIDS drugs at significantly reduced prices in many countries.

"With HIV/AIDS medicines, a disease that was once a virtual death sentence can now be controlled and treated as if it were a chronic disease," adds Tauzin. "And the new medicines our scientists are working on right now bring hope for even more promising results in the future."

To read the report on the PhRMA Web site, click on the following link: http://www.phrma.org/

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $43 billion in 2006 in discovering and developing new medicines. Industry wide research and investment reached a record $55.2 billion in 2006.

PhRMA Internet Address: http://phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://innovation.org

For information on the Partnership for Prescription Assistance, visit: http://pparx.org

For information on the danger of imported drugs, visit: http://buysafedrugs.info


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
2. Concentra Offers Flu Vaccines to Keep America Working
3. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Promising Cystic Fibrosis Compound on Track for Development
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016 Since its commercial introduction ... essential life science tool for conducting genetic studies in ... reveals in its new report that the industry sits ... powered by a range of new applications in the ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
(Date:5/25/2016)... , May 25, 2016 As ... Expo earlier this month, the numbers and momentum of ... to climb into the billions, more research and development ... 4th Edition State of Legal Marijuana Markets Report  from ... data-analysis firm, much of the increase in sector is ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the ... – London is home to Ontario’s leading day spa and one of Canada’s few ... began with a unique concept to combine spa services with hair and beauty ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... WaterField Designs, ... digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ideal ... canvas or ballistic nylon, the Duo is smartly designed for Dad’s grooming ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Spectrum Aquatics has ... new lift has been designed and built with the user in mind. , “Over ... consultants have informed us that an ADA 400 lbs lift is a necessary requirement ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... Interest ... a primary screening tool and as an orthogonal tool for RNAi hit validation. A ... functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed ...
(Date:5/31/2016)... ... May 31, 2016 , ... TeaZa® Energy, LLC announces ... on World No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be ... this summer. , The new flavor is best described as a juicy, taste ...
Breaking Medicine News(10 mins):